KRAS and pancreatic adenocarcinoma: KRAS mutations are prevalent in other malignancies, including PAAD and COAD, occurring in 90% and 45% of cases, respectively.[26] We found COA4 significantly overexpressed in these KRAS‐mutant tumors (Figure S8E,F, Supporting Information).